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PreviewsDesigning Effective Hybrid Toxins
A study of a well-designed androgen-mustard conju-
gate provides evidence supporting a novel mecha-
nism for its selective toxicity in androgen-receptor-
positive cancer cells [1]. This represents a solid step
forward on the path toward effective hybrid toxins for
targeted cancer therapy.
The concept of hybrid toxins emerged many years ago
as researchers sought to tame the non-specific toxicity
of standard antitumor agents by conjugating them to
targeting moieties. The hope for these hybrid toxins
was that the targeting element would direct them or
their action more selectively to the tumor and thereby
maintain their effectiveness at this site while sparing
the morbidity resulting from non-tumor organ toxicity.
Hybrid toxins have taken many forms—antibodies
conjugated to peptide toxins or enzymes to activate an-
titumor prodrugs; small-molecule ligands for cell-surface
or intracellular receptors conjugated to cytotoxic chemo-
therapeutics—and work on them has spanned many de-
cades. Nevertheless, progress in fulfilling their promise
has been slow in coming. Moreover, the history of hy-
brid-toxin development is filled with reports that claim
effectiveness based on a targeting mechanism that is
either quantitatively untenable or is poorly supported
by the details of the study [2].
For example, Estramustine (Figure 1A), a estradiol-
nitrogen mustard conjugate [3], was claimed to act by
binding to steroid receptors in prostate tumors and
thereby delivering the toxic mustard selectively to
these sites [4]. Although it is used to treat prostate can-
cer, Estramustine does not bind to steroid receptors,
and its antimitotic action appears to arise through a
mechanism very different from that originally claimed.
It binds to microtubule-associated proteins [5], an in-
teraction that does not even require the reactive chlo-
rines of the mustard.
In this issue of Chemistry & Biology, Marquis et al.
[1] (from the laboratories of Essigmann and McCroy)
describe the synthesis and evaluation of newly de-
signed androgen-mustard conjugates (Figure 1B). Not
only have they uncovered very interesting bioactivity of
their key conjugate, but their study also exemplifies
many of the elements of careful design and of appropri-
ate control experiments that are needed to advance the
promise of hybrid toxins in a rational manner [2, 6].
The authors of this report have a different perspec-
tive on how a hybrid toxin—specifically, a steroid-mus-
tard conjugate—might bring about a selective toxic ef-
fect in a receptor-positive cancer cell [1]. In contrast to
the traditional view that might be termed a “bind-then-
alkylate” mechanism (see Figure 1C, pathway A), they
envision actions by an alternative “alkylate-then-bind”
mechanism (Figure 1C, pathway B). The selective toxic
effect through pathway A is presumed to result fromselective uptake and retention of the steroid mustard
conjugate by receptor-positive cells and thereby lead
to a higher level of DNA alkylation in these cells. By
contrast, selective toxicity through pathway B is not en-
visioned to arise from selective alkylation, but rather
from an impairment of DNA repair in receptor-positive
cells (and possibly from other mechanisms). The bind-
ing of steroid receptors to steroids that are tethered to
sites of DNA alkylation is presumed to sterically block
access of DNA-repair enzymes to the lesion and
thereby trigger apoptotic pathways in the receptor-pos-
itive cells, but not in the receptor-negative cells in
which these lesions could be repaired. A secondary re-
sult of receptor binding to these DNA adducts might be
the sequestration of the receptor away from important
regulatory sites needed to support cell proliferation or
survival. Distinguishing between the two principal
mechanisms—pathway A versus pathway B—is a chal-
lenge; in fact, with a properly designed hybrid toxin,
both pathways might be active.
In the work described in this report [1], the authors
have built upon their careful prior studies with indole-
based estrogen-mustard conjugates [7–9] to construct
a new hybrid toxin, an androgen-mustard conjugate
(Figure 1B). In their design, a chlorambucil nitrogen
mustard moiety is connected through a 15-atom linker
to the high-affinity steroidal androgen; attachment to
the steroid is at the 11β position, known to be a substit-
uent-tolerant site. As an appropriate “toxin-inactive
control” compound, they have prepared a steroid con-
jugate with a nonreactive mustard analog in which the
reactive chlorines in the chlorambucil unit are replaced
with methoxyl groups. As a “nonbinding toxin control”
compound, they use chlorambucil itself.
The investigators then demonstrated that their an-
drogen conjugates, both the hybrid toxin and toxin-
inactive control compound, retain good affinity (Kd z
1 nM) for the androgen receptor (AR), ca. one-fifth that
of the in vivo active androgen 5α-dihydrotestosterone
(DHT). However, the AR binding affinity of the steroid-
mustard conjugate covalently attached to a model oli-
gonucleotide is 20-fold lower than that of the free hy-
brid toxin. Even with this reduction, they find that the
hybrid toxin has very favorable activities in cell culture
and tumor xenograft models.
In AR-positive prostate cancer (LNCaP) cells, the an-
drogen-mustard causes cell-cycle arrest and induces
apoptosis. Chlorambucil itself and the toxin-inactive
control steroid both cause cell-cycle arrest, but not
apoptosis. Detailed studies of important regulators of
the cell cycle and apoptosis, and other controls, support
the unique apoptotic activity of the androgen-mustard
conjugate. Particularly striking is the strong growth-sup-
pressive effect of the androgen-mustard conjugate on
LNCaP tumors grown as xenografts in nude mice,
where a 90% reduction in tumor growth rate is sus-
tained for many weeks. Notably, though, the compound
is cytostatic, not cytotoxic.
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720Figure 1. Steroid-Mustard Conjugates and Alternative Pathways Proposed for Their Action
Estramustine (A) is an active agent in prostate cancer treatment; it is proposed to act via pathway A, but it does not bind to steroid receptors.
The androgen-chlorambucil conjugate (B), the topic of this commentary [1], is selectively cytotoxic to androgen receptor-positive cells and
cytostatic in xenografts models, and it binds to the androgen receptor; its selective action is proposed to arise via pathway B. Selective
toxicity toward receptor-positive cells by pathway A (“bind-then-alkylate”) is proposed to involve selective uptake of the steroid-mustard
conjugate in receptor positive cells and selective DNA alkylation in these cells. By contrast, selective toxicity by pathway B (“alkylate-then-
bind”) is proposed to involve steric occlusion of DNA lesion repair by receptor binding to the tethered steroid; actions resulting from the
sequestration of the receptor from important promoter sites might also occur.That a well-designed androgen hybrid toxin is more l
sactive than are the toxin control and binding control
compounds in AR-positive cells and that it shows sub- t
istantial antitumor activity in an animal model of AR-
positive cancer are very interesting findings, but is this
ghybrid toxin working by a receptor-mediated “bind-
then-alkylate” or an “alkylate-then-bind” pathway (Fig- b
iure 1C), or is it working by a receptor-independent
pathway altogether? Although distinguishing between l
ethe two receptor-mediated pathways will be difficult, it
is worth considering how additional controls might more a
Cfirmly establish that the activities observed for the andro-
gen hybrid toxin are, indeed, receptor mediated [2, 6]. A
dIt would be helpful to have a more ideal nonbinding
toxin control compound than chlorambucil itself. Teth- m
tering chlorambucil to a steroid-like molecule with no
AR binding affinity would give an agent having cell up- h
stake and pharmacokinetic properties more like that ofthe androgen-chlorambucil conjugate. If it were stilless effective than the hybrid toxin, it would demon-
trate that the unique activities of the androgen-mus-
ard derived from its AR binding, not from differences
n cell-uptake rates or biodistribution.
The role of AR in mediating the effects of the andro-
en-chlorambucil hybrid toxin could be substantiated
y further controlled studies in cells. Comparative tox-
city studies in AR-positive versus AR-negative cell
ines might be informative, although inherent differ-
nces in the response of different cell lines to cytotoxic
gents might make interpretation of the results difficult.
omparing the activity of the hybrid toxin in the same
R-positive cells in which the AR has been knocked
own with siRNA could be especially informative, as
ight studies in which nonreactive AR ligands are used
o block the interaction of the androgen-chlorambucil
ybrid toxin with AR [6]. Further refinement in the de-
ign of androgen-toxin conjugates could also be con-
sidered. In particular, if one could develop compounds
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721in which the androgen-tethered DNA adduct retained
high affinity for the AR, then selectivity toxicity by an
“alkylate-then-bind” mechanism becomes more likely.
Although additional mechanistic questions remain,
the findings presented are both intriguing and promis-
ing. Considering the current limitations in the effec-
tiveness of both hormonal and cytotoxic chemotherapy
of prostate cancer, the results also represent a solid
step toward fulfilling the promise of hybrid toxins as
more selective cancer chemotherapeutic agents. Of
equal importance, this study nicely illustrates the care-
ful thought that needs to be given to the design of hy-
brid toxins and the careful controls that are required to
interpret mechanistically their activities in cell and ani-
mal model systems. This work will serve both as a stan-
dard and an inspiration for future studies in this area.
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